Every Form 4 that Johnson & Johnson (JNJ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow JNJ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JNJ filings page.
Johnson & Johnson executive Vanessa Broadhurst, EVP, Global Corporate Affairs, reported an equity compensation transaction. On February 9, 2026, she acquired 8,594 Performance Share Units (PSUs) at a price of $0 per unit under the company’s long-term incentive plan.
The PSUs were originally granted on February 13, 2023 and convert into shares of Johnson & Johnson common stock upon vesting. The reported 8,594-unit figure reflects the target PSUs adjusted based on achievement of performance conditions, which were certified on February 9, 2026. Following this transaction, she directly holds 8,594 derivative securities linked to common stock.
Johnson & Johnson executive Timothy Schmid, EVP and Worldwide Chair of MedTech, reported routine equity transactions on February 6, 2026. He exercised 15,571 employee stock options at $101.87 per share through an automatic exercise immediately before expiration, receiving the same number of common shares.
To cover the option exercise price and related taxes, 10,335 common shares were withheld at a value of $239.99 per share, leaving 22,125 common shares held directly after the transactions. He also reports indirect ownership of 745 shares through a 401(k) plan and 46 shares through an ESOP under the Johnson & Johnson Savings Plan.
Johnson & Johnson executive Kristen Mulholland, EVP and Chief HR Officer, reported routine equity activity involving stock options and common shares. On February 6, 2026, 5,625 employee stock options with a $101.87 exercise price were automatically exercised immediately before expiration, creating 5,625 shares of common stock.
To cover the option exercise price and related taxes, 3,335 common shares were withheld at a reference price of $239.99. After these transactions, Mulholland directly owned 16,409 shares of Johnson & Johnson common stock. The filing characterizes the option exercise as an automatic event tied to the option’s expiration.
Johnson & Johnson EVP and Chief TO and Risk Officer Kathryn E. Wengel reported an automatic exercise of employee stock options and related share withholding. On February 6, 2026, she exercised 38,945 employee stock options at $101.87 per share, receiving the same number of common shares.
To cover the option exercise price and taxes, 27,270 common shares were withheld at a value of $239.99 per share. After these transactions, she directly held 105,955.8735 Johnson & Johnson common shares, plus 281 shares held indirectly through an ESOP and 86 shares through a 401(k), both as of the plan reporting date.
Johnson & Johnson EVP and Chief Legal Officer Elizabeth Forminard reported an option exercise and related share sale. On 02/05/2026, she exercised employee stock options for 8,921 shares of common stock at $129.51 per share.
On the same date, 6,226 common shares coded "F" were sold in market trades at a weighted average price of $237.90, executed in multiple trades between $237.89 and $237.935. After these transactions, she directly held 15,548 shares of Johnson & Johnson common stock.
Johnson & Johnson CEO Joaquin Duato reported indirect stock sales by his spouse. On January 26, 2026, the spouse sold 51,218 Johnson & Johnson common shares at a weighted average price of $220.986 per share in multiple trades, and another 48,782 shares at a weighted average price of $221.484 per share.
After these transactions, the filing shows the spouse indirectly holding 79,634 shares and 30,852 shares in two accounts. Joaquin Duato is also shown as directly holding 275,967 common shares and 988 shares through a 401(k) plan as of the plan’s most recent reporting date.
Johnson & Johnson, as a reporting person and director of CVRx, Inc., filed an amended Form 4 to correct an earlier insider transaction report. Through its wholly owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., it sold 16,000 shares of CVRx common stock on 11/25/2025 at a weighted average price of $10.03, and 6,337 shares on 11/26/2025 at a weighted average price of $10.03. The shares on 11/25/2025 were sold in multiple trades between $10.00 and $10.22, and on 11/26/2025 between $10.00 and $10.23. After these sales, 4,024,861 CVRx shares were reported as indirectly beneficially owned by Johnson & Johnson through JJDC. The amendment states the 11/25/2025 sale was omitted from the original filing due to an administrative oversight.
Johnson & Johnson director reports deferred share units award
A Johnson & Johnson (JNJ) director reported receiving 185.533 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit. After this transaction, the director beneficially owns 5,058.0682 DSUs in total, held directly.
The DSUs were acquired by deferring the director’s cash retainer under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors. These units will be settled in cash when the director’s board service ends, and each DSU represents the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The total includes dividend-equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.
Johnson & Johnson director reports deferred share unit award
A Johnson & Johnson (JNJ) director reported receiving 247.378 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. After this transaction, the director beneficially owned 14,153.1187 DSUs in total.
The DSUs represent the fair market value of one share of Johnson & Johnson common stock and are to be settled in cash when the director’s service on the board ends. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend, keeping the director’s deferred compensation aligned with shareholder payouts.
Johnson & Johnson director Daniel E. Pinto reported a compensation-related equity transaction. On 12/09/2025, he acquired 154.611 Deferred Share Units (DSUs) under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors at a derivative security price of $202.12. Following this transaction, he beneficially owned 331.233 DSUs.
The DSUs represent deferred cash retainers and are to be settled in cash when his service as a director ends. Each DSU is tied to the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The reported balance also includes dividend equivalent rights accrued on DSUs he already held.
Johnson & Johnson director John Morikis reported buying company stock. On 11/26/2025, he acquired 1,250 shares of common stock at a price of $206.15 per share, coded as transaction type "P." After this purchase, he beneficially owned 1,848.51 shares, held directly. The Form 4 indicates the filing relates to one reporting person and shows no derivative securities transactions.
Johnson & Johnson filed a Form 4 reporting small open-market sales of CVRx, Inc. common stock held indirectly through its subsidiary Johnson & Johnson Innovation - JJDC, Inc. JJDC sold 500 CVRx shares on 11/21/2025 at a price of $10.00 per share and 2,200 shares on 11/24/2025 at a weighted average price of $10.06 per share. After these transactions, Johnson & Johnson, through JJDC, indirectly beneficially owned 4,047,198 CVRx common shares. The filing notes that the 11/24/2025 price reflects multiple trades between $10.00 and $10.10, and Johnson & Johnson undertakes to provide detailed trade breakdowns upon request.
Johnson & Johnson filed a Form 4 reporting open‑market sales of CVRx (CVRX) common stock by its subsidiary, Johnson & Johnson Innovation – JJDC, Inc. The filing lists sales of 52,332 shares at a weighted average price of $10.21 on 11/06/2025 and 200 shares at $10.00 on 11/07/2025. After these transactions, J&J indirectly beneficially owned 4,050,898 CVRx shares through JJDC. Prices for the 11/06 trades ranged from $10.00 to $10.49 per share.
Johnson & Johnson (JNJ) insider trade: EVP, Innovative Medicine, R&D, John C. Reed exercised 21,721 employee stock options at $157.92 per share and sold 21,721 common shares at a weighted average price of $192.7072 on 10/17/2025. Following these transactions, he directly beneficially owned 10,658 common shares and held 43,442 derivative securities (options). The sale price reflects multiple trades between $192.69 and $192.87.